Literature DB >> 33844107

The positive effect of pregnancy in rheumatoid arthritis and the use of medications for the management of rheumatoid arthritis during pregnancy.

Uday Raj Sharma1, Akhila Nediyedath Rathnakaran2, B P Prudhvi Raj3, Gayathry Padinjakkara3, Akanksh Das3, Surendra Vada3, Manjunatha P Mudagal3.   

Abstract

Rheumatoid arthritis (RA) is an autoimmune systemic inflammatory disorder that is mostly characterised by progressive symmetrical joint destruction, particularly in the wrist and fingers, while it may also affect additional joints and several organs, such as the skin, heart, blood vessels, and lungs. It is identified by raised anti-rheumatoid factor and anti-cyclic citrullinated peptide antibodies. The chemical mediators involved in the activity of RA are IL-1β, TNF-α, and IL-6. Pregnancy exerts a positive effect on RA that helps to modulate the disease condition. Different hypotheses are recommended to explain the ameliorating effect of pregnancy in RA. RA cannot be completely cured. The treatment goal is the attrition of pain and inflammation and the further progression of the disease. Long-term management of RA is carried out using disease-modifying antirheumatic drugs (DMARDs). Therapy of acute flares can be done with Non-steroidal anti-inflammatory drugs (NSAIDs) accompanied by ad interim usage of glucocorticoids. Biologic response modifiers are also available; they act by abolishing the activity of T- cells. However, it is necessary to select the correct treatment regimen when it comes to the management of RA in pregnancy.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Biologics; Corticosteroids; DMARDs; NSAIDs; Pregnancy; Rheumatoid arthritis

Mesh:

Substances:

Year:  2021        PMID: 33844107     DOI: 10.1007/s10787-021-00808-9

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  73 in total

1.  Adalimumab level in breast milk of a nursing mother.

Authors:  Shomron Ben-Horin; Miri Yavzori; Lior Katz; Orit Picard; Ella Fudim; Yehuda Chowers; Alon Lang
Journal:  Clin Gastroenterol Hepatol       Date:  2010-01-06       Impact factor: 11.382

2.  A patient's wish: anakinra in pregnancy.

Authors:  C T Berger; M Recher; U Steiner; T M Hauser
Journal:  Ann Rheum Dis       Date:  2009-11       Impact factor: 19.103

3.  Adult and two children with fetal methotrexate syndrome.

Authors:  E V Bawle; J V Conard; L Weiss
Journal:  Teratology       Date:  1998-02

Review 4.  Non-steroidal anti inflammatory drugs, glucocorticoids and disease modifying anti-rheumatic drugs for the management of rheumatoid arthritis before and during pregnancy.

Authors:  Bonnie L Bermas
Journal:  Curr Opin Rheumatol       Date:  2014-05       Impact factor: 5.006

5.  In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta.

Authors:  A T Blanford; B E Murphy
Journal:  Am J Obstet Gynecol       Date:  1977-02-01       Impact factor: 8.661

6.  Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother.

Authors:  L M Buckley; C A Bullaboy; L Leichtman; M Marquez
Journal:  Arthritis Rheum       Date:  1997-05

7.  The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis.

Authors:  B Harrison; W Thomson; D Symmons; B Ollier; N Wiles; T Payton; E Barrett; A Silman
Journal:  Arthritis Rheum       Date:  1999-10

8.  Azathioprine treatment during lactation.

Authors:  L A Christensen; J F Dahlerup; M J Nielsen; J F Fallingborg; K Schmiegelow
Journal:  Aliment Pharmacol Ther       Date:  2008-08-30       Impact factor: 8.171

9.  Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients.

Authors:  María Chaparro; Ingrid Ordás; Eduard Cabré; Valle Garcia-Sanchez; Guillermo Bastida; Mireia Peñalva; Fernando Gomollón; Esther García-Planella; Olga Merino; Ana Gutiérrez; Maria Esteve; Lucia Márquez; Maria Garcia-Sepulcre; Joaquín Hinojosa; Isabel Vera; Fernando Muñoz; Juan L Mendoza; Jose L Cabriada; Miguel A Montoro; Manuel Barreiro-de Acosta; G Ceña; Cristina Saro; Xavier Aldeguer; Jesús Barrio; José Maté; Javier P Gisbert
Journal:  Inflamm Bowel Dis       Date:  2013-06       Impact factor: 5.325

10.  Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk.

Authors:  C M Berlin; S J Yaffe
Journal:  Dev Pharmacol Ther       Date:  1980
View more
  2 in total

1.  Risk factors for adverse pregnancy outcomes in women with rheumatoid arthritis and follow-up of their offspring.

Authors:  Liang Luo; Xuerong Li; Rui Yan; Huijuan Zhang; Chun Li
Journal:  Clin Rheumatol       Date:  2022-06-13       Impact factor: 3.650

Review 2.  Creating an Optimal In Vivo Environment to Enhance Outcomes Using Cell Therapy to Repair/Regenerate Injured Tissues of the Musculoskeletal System.

Authors:  David A Hart; Norimasa Nakamura
Journal:  Biomedicines       Date:  2022-07-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.